Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tapestry, Inc. (TPR) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

TPR trades at $140.73, up 0.57% today, with a bearish technical signal but strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.24. Valuation ratios are elevated (P/E 42.91, P/B 41.67), though profitability metrics like a 76.18% gross margin and 55.74% ROE remain robust. Recent news highlights digital growth and Gen Z engagement, with a $0.40 dividend paid in June 2026.

The outlook is mixed: bullish analyst consensus ($184.14 price target, 75.61% buy ratings) contrasts with technical bearishness and a high debt load. Key risks include sensitivity to consumer spending and execution of growth initiatives. Upside hinges on sustained earnings beats and margin expansion, while debt management and competitive pressures pose challenges.